Biological Planning of Radiation Dose Based on In Vivo Dosimetry for Postoperative Vaginal-Cuff HDR Interventional Radiotherapy (Brachytherapy).

HDR brachytherapy biological planning endometrial cancer in vivo dosimetry interventional radiotherapy vaginal-cuff brachytherapy

Journal

Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304

Informations de publication

Date de publication:
06 Nov 2021
Historique:
received: 25 09 2021
revised: 28 10 2021
accepted: 04 11 2021
entrez: 27 11 2021
pubmed: 28 11 2021
medline: 28 11 2021
Statut: epublish

Résumé

(1) Background: Postoperative vaginal-cuff HDR interventional radiotherapy (brachytherapy) is a standard treatment in early-stage endometrial cancer. This study reports the effect of in vivo dosimetry-based biological planning for two different fractionation schedules on the treatment-related toxicities. (2) Methods: 121 patients were treated. Group A (82) received 21 Gy in three fractions. Group B (39) received 20 Gy in four fractions. The dose was prescribed at a 5 mm depth or to the applicator surface according to the distance between the applicator and the rectum. In vivo dosimetry measured the dose of the rectum and/or urinary bladder. With a high measured dose, the dose prescription was changed from a 5 mm depth to the applicator surface. (3) Results: The median age was 66 years with 58.8 months mean follow-up. The dose prescription was changed in 20.7% of group A and in 41% of group B. Most toxicities were grade 1-2. Acute urinary toxicities were significantly higher in group A. The rates of acute and late urinary toxicities were significantly higher with a mean bladder dose/fraction of >2.5 Gy and a total bladder dose of >7.5 Gy. One patient had a vaginal recurrence. (4) Conclusions: Both schedules have excellent local control and acceptable rates of toxicities. Using in vivo dosimetry-based biological planning yielded an acceptable dose to the bladder and rectum.

Identifiants

pubmed: 34829858
pii: biomedicines9111629
doi: 10.3390/biomedicines9111629
pmc: PMC8615499
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Gynecol Oncol. 2012 Nov;127(2):351-5
pubmed: 22850411
Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1089-1109
pubmed: 30581199
Phys Med. 2019 Mar;59:151-157
pubmed: 30852055
Brachytherapy. 2018 Nov - Dec;17(6):1023-1029
pubmed: 30150015
Phys Med. 2019 Feb;58:1-7
pubmed: 30824140
J Natl Compr Canc Netw. 2021 Aug 01;19(8):888-895
pubmed: 34416706
Int J Gynecol Cancer. 2012 Sep;22(7):1281-8
pubmed: 22864336
Int J Gynecol Cancer. 2019 Oct;29(8):1264-1270
pubmed: 31320487
Phys Med. 2020 Jan;69:52-60
pubmed: 31830631
Phys Imaging Radiat Oncol. 2020 Sep 28;16:1-11
pubmed: 33458336
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Contemp Brachytherapy. 2018 Aug;10(4):315-320
pubmed: 30237815
Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1268-77
pubmed: 17336226
Gynecol Oncol. 2008 Jan;108(1):77-83
pubmed: 17936341
Brachytherapy. 2012 Jan-Feb;11(1):58-67
pubmed: 22265439
Radiother Oncol. 2020 Oct;151:273-279
pubmed: 32798597
Lancet. 2010 Mar 6;375(9717):816-23
pubmed: 20206777
Brachytherapy. 2005;4(3):236-40
pubmed: 16182225
Radiother Oncol. 2015 Jul;116(1):143-8
pubmed: 26194144
Gynecol Oncol. 2019 Mar;152(3):439-444
pubmed: 30876486
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):e75-80
pubmed: 22330985
Cancer Manag Res. 2017 Aug 09;9:351-362
pubmed: 28848362
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
J Clin Oncol. 2009 Jul 20;27(21):3547-56
pubmed: 19546404
Obstet Gynecol. 1980 Oct;56(4):419-27
pubmed: 6999399
Int J Radiat Oncol Biol Phys. 1990 Feb;18(2):305-14
pubmed: 2303363
J Contemp Brachytherapy. 2021 Apr;13(2):231-243
pubmed: 33897798
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1249-55
pubmed: 21676554
J Contemp Brachytherapy. 2020 Feb;12(1):61-66
pubmed: 32190072
Radiother Oncol. 2021 Feb;155:160-166
pubmed: 33159971
Clin Transl Oncol. 2016 Sep;18(9):925-30
pubmed: 26661111
Phys Med. 2017 Sep;41:5-12
pubmed: 28499627
Brachytherapy. 2017 Jan - Feb;16(1):147-152
pubmed: 28029590
Phys Eng Sci Med. 2021 Sep;44(3):773-783
pubmed: 34191272

Auteurs

Tamer Soror (T)

Radiation Oncology Department, University of Lübeck/UKSH-CL, 23562 Lübeck, Germany.
National Cancer Institute (NCI), Radiation Oncology Department, Cairo University, Giza 12613, Egypt.

Ramin Chafii (R)

Radiation Oncology Department, University of Lübeck/UKSH-CL, 23562 Lübeck, Germany.

Valentina Lancellotta (V)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy.

Luca Tagliaferri (L)

UOC Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, 00168 Roma, Italy.

György Kovács (G)

Gemelli-INTERACTS, Università Cattolica del Sacro Cuore, 00168 Roma, Italy.

Classifications MeSH